It could become the first publicly listed company focused on AI-driven nanodelivery.
Written by IPO Zaozhidao
Published on
21 Apr 2026
7 mins read
On April 19, Metis TechBio (stylized as “METiS TechBio”) announced that it had cleared its listing hearing at Hong Kong Exchanges and Clearing (HKEX), a key step toward a Hong Kong IPO.
Listing would mark the third AI pharma firm in the city, highlighting investor enthusiasm for AI-driven drug development
Hong Kong-listed AI-driven drug delivery innovation company Metis TechBio Co Ltd said on Tuesday it had granted Boulevard Bio, an…
AI-powered drug developer Metis TechBio leads group that includes developers of autonomous driving technology and industrial…
Its optical computing solutions could address key bottlenecks in AI systems.
Cambricon becomes first STAR Market stock to hit 1-trillion-yuan market cap, Neolix gets nod for autonomous delivery tests in…
MetaX Integrated Circuits plans a Hong Kong secondary listing after its Shanghai IPO saw shares surge 693% on debut. The GPU…
